Scholar Rock Holding Corporation Common Stock (SRRK)
Stock · NASDAQ · Health Care
$39.9as of 10/16/2026
Price chart
Active signals
SRRK Signal Track Record
How signals performed across all stocks →What SRRK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +2.9% | 59% | September 8, 2026 |
| Bollinger Band Breakdown | 22 | -0.3% | 50% | September 14, 2026 |
| Bollinger Band Breakout | 19 | -5.5% | 47% | August 19, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -8.2% | 45% | September 21, 2026 |
| Any 20-session window (baseline) | +0.4% | 51% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SRRK
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platfo…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 289
- Website
- scholarrock.com/
Fundamentals
- 1-day range
- $38.69$41.28
- Market cap
- $6.31B
- P/E (trailing)
- —
- P/E (forward)
- -15.81
- EPS (trailing)
- $-3.30
- Dividend yield
- —
- Beta
- 0.75
- Avg. volume
- 1.56M
How Scholar Rock Holding Corporation Common Stock Makes Money
Where the revenue actually goes — FY2022 annual results
Source: 10-K filed Mar 7, 2023 · via SEC EDGAR / Finnhub
Forecasts
16 analyst ratings
Scholar Rock Holding Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- SRRKScholar Rock Holding Corporation Common Stock$39.9▼ 1.82%Market cap $6.31BP/E —$27.07$61.76
- CGONCG Oncology Inc. Common stock$59.85▼ 3.25%Market cap $6.60BP/E —$35.8$80.97
- TWSTTwist Bioscience Corporation Common Stock$132.75▼ 8.13%Market cap $6.84BP/E —$23.3$219.71
- CRSPCRISPR Therapeutics AG Common Shares$49.25▼ 4.41%Market cap $4.99BP/E —$44.12$75.06
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SRRK Scholar Rock Holding Corporation Common Stock | $6.31B | — | $39.9 | ▼ 1.82% | $27.07$61.76 |
| CGON CG Oncology Inc. Common stock | $6.60B | — | $59.85 | ▼ 3.25% | $35.8$80.97 |
| TWST Twist Bioscience Corporation Common Stock | $6.84B | — | $132.75 | ▼ 8.13% | $23.3$219.71 |
| CRSP CRISPR Therapeutics AG Common Shares | $4.99B | — | $49.25 | ▼ 4.41% | $44.12$75.06 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular Atrophybenzinga · 10/8/2026
- Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)Yahoo · 10/8/2026
- Scholar Rock Refiles Marketing Authorisation Application With EMA For Apitegromab To Treat Children And Adults With Spinal Muscular AtrophyBenzinga · 10/8/2026
- Scholar Rock Holding Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · 10/5/2026
- 3 drug targets pharma is betting on nextYahoo · 10/2/2026
- FDA Decision Watch: BMY, EGTX Face Key Decisions This Week As BFRI, SRRK And MIRM Score Early ApprovalsYahoo · 9/28/2026
- Scholar Rock Poised for De-risked Commercial Ramp in Neuromuscular Space, Wedbush SaysYahoo · 9/25/2026
- Truist Securities Maintains Buy on Scholar Rock Holding, Raises Price Target to $77Benzinga · 9/24/2026
- Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/21/2026
Insider Activity
Insider Actions →- Keith Woods · September 24, 2026 · Gift48.0K
- Hallal David · September 21, 2026 · Gift36.7K
- FLIER JEFFREY S. · July 1, 2026 · Sale15 @ $54.88
- FLIER JEFFREY S. · July 1, 2026 · Sale1.5K @ $54.24
- FLIER JEFFREY S. · July 1, 2026 · Sale1.6K @ $53.53
- Reed Joshua · July 1, 2026 · Sale948 @ $54.28
- Reed Joshua · July 1, 2026 · Sale2.1K @ $53.5
- Katie Peng · July 1, 2026 · Sale21 @ $54.96
- Katie Peng · July 1, 2026 · Sale2.4K @ $54.25
- Katie Peng · July 1, 2026 · Sale3.0K @ $53.56
- Kristina Burow · July 1, 2026 · Sale948 @ $54.28
- Kristina Burow · July 1, 2026 · Sale2.1K @ $53.49
- Gilman Michael · July 1, 2026 · Sale43 @ $54.81
- Gilman Michael · July 1, 2026 · Sale1.2K @ $54.23
- Gilman Michael · July 1, 2026 · Sale1.3K @ $53.54
Institutional Ownership
March 31, 2026
- Total shares held
- 132.19M
- Total value held
- $6.17B
- Institutional holders
- 272
- Unknown17.24M
- Unknown10.83M
- Unknown9.07M
- Unknown7.47M
- Unknown6.90M
- Unknown6.72M
- Unknown6.21M
- Unknown4.18M
- Unknown4.03M
- Unknown3.89M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Scholar Rock Refiles Apitegromab Application With EMA
Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.
Scholar Rock Refiles Apitegromab Application With EMA. Scholar Rock has resubmitted its marketing authorization application to the European Medicines Agency for apitegromab, a treatment for spinal muscular atrophy in children and adults. This regulatory step follows the company's recent release of its Q2 2026 financial results. The stock is currently trading near its 52-week low, which provides context for the significance of this regulatory update.